SCHEMBL25202171

SCHEMBL25202171

COc1ccc(/C=C/C(=O)c2ccc(O)cc2)cc1COc1cc(C)ccc1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.67
▸ KMT2A Q03164 7/20 0.67
▸ LMNA P02545 5/20 0.67
▸ ALDH1A1 P00352 5/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ MAPT P10636 7/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ THRB P10828 1/20 0.59
▸ RECQL P46063 1/20 0.58
▸ CTSL P07711 1/20 0.57
▸ CXCL12 P48061 1/20 0.56
▸ ABCG2 Q9UNQ0 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ POLB P06746 2/20 0.52
▸ MAOA P21397 1/20 0.52
▸ MAOB P27338 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ CAPN1 P07384 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30383487 1.00 MEN1 (0.67) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25209839 0.91 MEN1 (0.66) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL30383181 0.91 MEN1 (0.66) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25217693 0.88 RECQL (0.74) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25198520 0.88 MEN1 (0.62) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL30383445 0.88 MEN1 (0.62) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25195235 0.87 MEN1 (0.82) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25198483 0.87 CYP19A1 (0.64) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25223533 0.86 ALDH1A1 (0.60) MEN1KMT2ALMNAALDH1A1KDM4E
SCHEMBL25284637 0.86 ALDH1A1 (0.60) MEN1KMT2ALMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 — — US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 — — US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 — — US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MEN1 3367/4885KMT2A 2792/4885LMNA 1180/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885LMNA 1817/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MEN1 2457/4885KMT2A 3188/4885LMNA 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback